BioAtla, Inc. financial data

Symbol
BCAB on Nasdaq
Location
San Diego, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 183% % -53%
Debt-to-equity -503% % -633%
Return On Equity 780% %
Return On Assets -194% % -101%

Shares

Label TTM Value / Value Unit Change %
Common Stock, Shares, Outstanding 58,792,088 shares 22%
Entity Public Float $59,900,000 USD -34%
Common Stock, Value, Issued $6,000 USD 20%
Weighted Average Number of Shares Outstanding, Basic 58,745,343 shares 22%
Weighted Average Number of Shares Outstanding, Diluted 58,745,343 shares 22%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $47,228,000 USD -36%
General and Administrative Expense $19,066,000 USD -18%
Operating Income (Loss) $66,294,000 USD 23%
Net Income (Loss) Attributable to Parent $64,707,000 USD 21%
Earnings Per Share, Basic -1 USD/shares 32%
Earnings Per Share, Diluted -1 USD/shares 32%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $8,320,000 USD -85%
Assets, Current $9,670,000 USD -84%
Property, Plant and Equipment, Net $324,000 USD -64%
Operating Lease, Right-of-Use Asset $5,751,000 USD 654%
Other Assets, Noncurrent $163,000 USD
Assets $15,908,000 USD -74%
Accounts Payable, Current $5,851,000 USD 100%
Liabilities, Current $17,984,000 USD -7.6%
Operating Lease, Liability, Noncurrent $5,008,000 USD
Liabilities $47,145,000 USD 20%
Retained Earnings (Accumulated Deficit) $535,862,000 USD -14%
Stockholders' Equity Attributable to Parent $31,237,000 USD -236%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $31,237,000 USD -236%
Liabilities and Equity $15,908,000 USD -74%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $16,288,000 USD 47%
Net Cash Provided by (Used in) Financing Activities $395,000 USD -2938%
Net Cash Provided by (Used in) Investing Activities $0 USD
Common Stock, Shares Authorized 350,000,000 shares 0%
Common Stock, Shares, Issued 58,792,088 shares 22%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $8,320,000 USD -85%
Deferred Tax Assets, Valuation Allowance $102,655,000 USD 20%
Deferred Tax Assets, Gross $102,838,000 USD 19%
Operating Lease, Liability $6,181,000 USD 394%
Lessee, Operating Lease, Liability, to be Paid $7,858,000 USD 519%
Property, Plant and Equipment, Gross $7,681,000 USD 0%
Operating Lease, Liability, Current $1,173,000 USD -6.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two $1,484,000 USD 76%
Lessee, Operating Lease, Liability, to be Paid, Year One $122,000 USD -71%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 143%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $1,677,000 USD 8726%
Lessee, Operating Lease, Liability, to be Paid, Year Three $1,528,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $33,799,000 USD 35%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 200,000,000 shares 0%
Unrecognized Tax Benefits $4,582,000 USD 27%
Lessee, Operating Lease, Liability, to be Paid, Year Four $1,574,000 USD
Operating Lease, Payments $1,269,000 USD -17%
Additional Paid in Capital $504,619,000 USD 2.1%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $183,000 USD -24%
Deferred Tax Assets, Net of Valuation Allowance $183,000 USD -66%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%